A Bet that Myostatins Can Muscle Out Obesity
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
A Bet that Myostatins Can Muscle Out Obesity
-
Narrated by:
-
By:
About this listen
GLP-1 agonists have been a breakthrough for the treatment of obesity, a global problem with serious health risks. While the benefits of these therapies are seen as outweighing the risks, there have been some concerns about the loss of muscle mass, particularly in older people using these drugs. iBio is developing next-generation obesity therapies that may be able to be used in combination with GLP-1 agonists or by themselves. Its lead experimental therapy is a myostatin inhibitor, part of a class of therapies that have been of interest to treat muscle wasting. We spoke to Martin Brenner, CEO and chief scientific officer of iBIO, about obesity, the limits of GLP-1 agonists, and the potential for myostatin inhibitors alone or in combination with GLP-1 agonists.